Cost impact of BTKi selection in Medicare patients with CLL

That is the title of my paper out today in the Journal of Comparative Effectiveness Research written with co-authors Adam Kittai, Dipen Patel, Nadine Zawadzki, Vikram Shetty, Yazan Barqawi, and Joanna Rhodes. The abstract is below. Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and…

Read More

Fighting Staff Shortages With Scholarships, California Bill Aims To Boost Mental Health Courts

A seemingly innocuous proposal to offer scholarships for mental health workers in California’s new court-ordered treatment program has sparked debate over whether the state should prioritize that program or tackle a wider labor shortage in behavioral health services. Nine counties have begun rolling out the Community Assistance, Recovery, and Empowerment Act, which Gov. Gavin Newsom…

Read More

Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug

Saniona’s drug candidate could expand Jazz Pharmaceuticals portfolio in epilepsy. But this preclinical small molecule will need to show advantages in safety and efficacy to compete with Biohaven Pharmaceuticals and Xenon Pharmaceuticals, each with clinical-stage drugs that hit the same epilepsy target. The post Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective…

Read More